Press releases

12 Dec 2016

MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC

read more
18 May 2016

Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients

read more
12 Apr 2016

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

read more